Ivan Carrera
Overview
Explore the profile of Ivan Carrera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
417
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cacabelos R, Martinez-Iglesias O, Cacabelos N, Carrera I, Corzo L, Naidoo V
Life (Basel)
. 2025 Jan;
14(12.
PMID: 39768263
Alzheimer's disease (AD) is a complex/multifactorial brain disorder involving hundreds of defective genes, epigenetic aberrations, cerebrovascular alterations, and environmental risk factors. The onset of the neurodegenerative process is triggered decades...
2.
Carrera I, Corzo L, Martinez-Iglesias O, Naidoo V, Cacabelos R
Pharmaceuticals (Basel)
. 2023 Sep;
16(9).
PMID: 37765114
Neurodegeneration, characterized by the progressive deterioration of neurons and glial cells, is a feature of Alzheimer's disease (AD). The present study aims to demonstrate that the onset and early progression...
3.
Martinez-Iglesias O, Naidoo V, Carrera I, Carril J, Cacabelos N, Cacabelos R
Biology (Basel)
. 2023 Sep;
12(9).
PMID: 37759556
Pharmacogenetics and DNA methylation influence therapeutic outcomes and provide insights into potential therapeutic targets for brain-related disorders. To understand the effect of genetic polymorphisms on drug response and disease risk,...
4.
Martinez-Iglesias O, Naidoo V, Corzo L, Carrera I, Seoane S, Rodriguez S, et al.
Biology (Basel)
. 2023 Jun;
12(6).
PMID: 37372091
Dyslipidemia is a significant risk factor for cardiovascular disease and stroke. Our recent findings showed that RCI-1502, a bioproduct derived from the muscle of the European S. pilchardus, has lipid-lowering...
5.
Martinez-Iglesias O, Naidoo V, Carrera I, Corzo L, Cacabelos R
Pharmaceuticals (Basel)
. 2023 Jun;
16(2).
PMID: 37259364
Neurodegenerative disorders (NDDs) are major health issues in Western countries. Despite significant efforts, no effective therapeutics for NDDs exist. Several drugs that target epigenetic mechanisms (epidrugs) have been recently developed...
6.
Carrera I, Corzo L, Naidoo V, Martinez-Iglesias O, Cacabelos R
Int J Med Sci
. 2023 Mar;
20(3):292-306.
PMID: 36860672
Obesity is a major health challenge worldwide, with implications for diabetes, hypertension and cardiovascular disease (CVD). Regular consumption of dark-meat fish is linked to a lower incidence of CVD and...
7.
Martinez-Iglesias O, Naidoo V, Carrera I, Corzo L, Cacabelos R
Pharmaceutics
. 2022 Nov;
14(11).
PMID: 36432638
Alzheimer's disease (AD), the most common cause of dementia, causes irreversible memory loss and cognitive deficits. Current AD drugs do not significantly improve cognitive function or cure the disease. Novel...
8.
Martinez-Iglesias O, Naidoo V, Carrera I, Cacabelos R
Int J Mol Sci
. 2022 Mar;
23(5).
PMID: 35269588
Alzheimer's Disease (AD) is a major health problem worldwide. The lack of efficacy of existing therapies for AD is because of diagnosis at late stages of the disease, limited knowledge...
9.
Martinez-Iglesias O, Carrera I, Naidoo V, Cacabelos R
Life (Basel)
. 2022 Jan;
12(1).
PMID: 35054489
Novel and effective chemotherapeutic agents are needed to improve cancer treatment. Epidrugs are currently used for cancer therapy but also exhibit toxicity. Targeting the epigenetic apparatus with bioproducts may aid...
10.
Cacabelos R, Carrera I, Martinez-Iglesias O, Cacabelos N, Naidoo V
Expert Opin Drug Discov
. 2021 Jul;
16(12):1415-1440.
PMID: 34330186
Alzheimer's disease models (ADMs) are currently used for drug development (DD). More than 20,000 molecules were screened for AD treatment over decades, with only one drug (Aducanumab)FDA-approved over the past...